Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer
Vivek Subbiah(Sarah Cannon), Jie Wu(University of Oklahoma Health Sciences Center), J. Bryan Iorgulescu(Broad Institute), Behrang Amini(The University of Texas MD Anderson Cancer Center), Mohamed A. Gouda(The University of Texas MD Anderson Cancer Center), Funda Meric‐Bernstam(The University of Texas MD Anderson Cancer Center), Ramona Dadu(The University of Texas MD Anderson Cancer Center), Mimi I. Hu(The University of Texas MD Anderson Cancer Center), Steven I. Sherman(The University of Texas MD Anderson Cancer Center), Maria E. Cabanillas(The University of Texas MD Anderson Cancer Center), Tao Shen(Baylor College of Medicine), Keyur Patel(The University of Texas MD Anderson Cancer Center), Luz E. Castellanos(The University of Texas MD Anderson Cancer Center)
Cited by 24
Related Papers
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial
|Journal of Clinical Oncology|2023|882
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers
|New England Journal of Medicine|2020|766